|By PR Newswire||
|August 26, 2013 09:09 AM EDT||
NEW YORK, Aug. 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies.
There are today 881 companies plus partners developing 1527 biological drugs in 3359 developmental projects in cancer. In addition, there are 24 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 889 drugs. Biologicals In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 604 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 566 out of the 570 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 82 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
How May Drug Pipeline Update Be of Use?* Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.Drug Pipeline Update at a Glance
InvestigatorsIncludes more than 881 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & SynonymsLists commercial, generic and code names for drugs.
This Drug Pipeline Update contains 1527 biological drugs in development, which have a total of 3359 developmental projects in cancer. In addition there are suspended and ceased drugs.
Pipeline Breakdown According to Number of Drugs
Phase III# 109
Phase II# 371
Phase I# 405
No Data# 12
Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Included biological drugs are also in development for 337 other indications, where of 115 are different cancer indications.
Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
TargetsMutationsAll targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 566 out of the 570 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
The identity of available biological structures on 349 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 4087 structures available today among drug targets.
Identified drugs are linked to more than 604 different targets, divided into 82 classifications of molecular function:- Acid phosphatase activity- Antigen binding- ATPase activity- Auxiliary transport protein activity- B cell receptor activity- Binding- Carboxy-lyase activity- Carboxypeptidase activity- Catalytic activity- Cell adhesion molecule activity- Chaperone activity- Chemokine activity- Cofactor binding- Complement activity- Cysteine-type peptidase activity- Cytokine activity- Cytoskeletal protein binding- Deaminase activity- Defense/immunity protein activity- DNA binding- DNA repair protein- DNA topoisomerase activity- DNA-directed DNA polymerase activity- DNA-directed RNA polymerase activity- DNA-methyltransferase activity- Extracellular ligand-gated ion channel activity- Extracellular matrix structural constituent- Fucosyltransferase activity- G-protein coupled receptor activity- Growth factor activity- Growth factor binding- GTPase activator activity- GTPase activity- Guanylate cyclase activity- Heat shock protein activity- Hormone activity- Hydrolase activity- Intracellular ligand-gated ion channel activity- Isomerase activity- Kinase activity- Kinase binding- Kinase regulator activity- Ligand-dependent nuclear receptor activity- Ligase activity- Lipid kinase activity- Lipid phosphatase activity- Metallopeptidase activity- MHC class I receptor activity- Molecular function unknown- Motor activity- Oxidoreductase activity- Peptidase activity- Peptide hormone- Peroxidase activity- Protease inhibitor activity- Protein binding- Protein serine/threonine kinase activity- Protein threonine/tyrosine kinase activity- Protein tyrosine/serine/threonine phosphatase activity- Protein-tyrosine kinase activity- Receptor activity- Receptor binding- Receptor signaling complex scaffold activity- Receptor signaling protein serine/threonine kinase activity- Receptor signaling protein tyrosine phosphatase activity- RNA binding- RNA-directed DNA polymerase activity- Serine-type peptidase activity- Signal transducer activity- Structural constituent of cytoskeleton- Structural molecule activity- Superoxide dismutase activity- T cell receptor activity- Transcription factor activity- Transcription regulator activity- Transferase activity- Translation regulator activity- Transmembrane receptor activity- Transmembrane receptor protein tyrosine kinase activity- Transporter activity- Ubiquitin-specific protease activity- Unclassified
Identified targets are categorized into 38 different primary and alternate sub-cellular localizations:
- Apical membrane
- Cell junction
- Cell surface
- Clathrin-coated vesicle
- Cytoplasmic vesicle
- Early endosome
- Endoplasmic reticulum
- Extracellular matrix
- Golgi apparatus
- Golgi membrane
- Immunological synapse
- Integral to membrane
- Late endosome
- Membrane fraction
- Mitochondrial matrix
- Mitochondrial membrane
- Perinuclear region
- Perinuclear vesicle
- Peroxisomal matrix
- Plasma membrane
- Sarcoplasmic reticulum
- Secretory granule
- Secretory vesicle
- Soluble fraction
Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.
Target Expression Profile
Direct links are provided from inside the application to 716 protein expression profiles of 470 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway ReferalsIdentified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.- BioCarta# 265 Pathways- KEGG# 194 Pathways- NCI-Nature# 251 Pathways- NetPath# 32 Pathways
Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
MechanismIn total there are different drug mechanism of action represented in this Drug Pipeline Update.
Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
CompoundIdentified drug compounds are described by:
Compound type, Chemical name, CAS Number and molecular weight
Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.
Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:
Drug Name & SynonymsPresentation of drug name and synonyms
Principal Company & Partners
Presentation of principal company and partners
Target and Molecular Function of TargetDescribed target(s) is/are presented with:Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function
Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
MutationAll targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Targeted PathwaysDescribed target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Drug mechanism of action
Developmental ProjectsSummary field of developmental projects for the drug, including indication, developmental stage and status.Example:Cancer, myeloma – Phase II Clinical Trial – ActiveCancer, prostate – Phase III Clinical Trial – Ceased
Short introduction to drug
Compound DataCompound type, Chemical name, CAS Number and molecular weight
Available patent information related to the drug is presented here.
Fillings and ApprovalsApprovals and submissionsAnalyst comments
Deals & Licensing
Collaborations and deals
Availability for licensing
Phase IV DataAvailable Phase IV development data, developmental history and scientific data.
Phase III Data
Available Phase III development data, developmental history and scientific data.
Phase II DataAvailable Phase II development data, developmental history and scientific data.
Phase I Data
Available Phase I development data, developmental history and scientific data.
Phase 0 DataAvailable Phase 0 development data, developmental history and scientific data.
Available preclinical development data, developmental history and scientific data.
Discovery DataAvailable discovery development data, developmental history and scientific data.
Search, Find and Filter Panel with Initial Result Presentation
With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
- Direct links to company web pages of companies
Dynamic Report GeneratorOur dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.
System Requirements- Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)- Browser Application (Internet Explorer)- Internet access (to access related internet resources)
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...
Dec. 9, 2016 08:00 PM EST Reads: 1,011
An IoT product’s log files speak volumes about what’s happening with your products in the field, pinpointing current and potential issues, and enabling you to predict failures and save millions of dollars in inventory. But until recently, no one knew how to listen. In his session at @ThingsExpo, Dan Gettens, Chief Research Officer at OnProcess, discussed recent research by Massachusetts Institute of Technology and OnProcess Technology, where MIT created a new, breakthrough analytics model for ...
Dec. 9, 2016 07:45 PM EST Reads: 688
IoT is rapidly changing the way enterprises are using data to improve business decision-making. In order to derive business value, organizations must unlock insights from the data gathered and then act on these. In their session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, and Peter Shashkin, Head of Development Department at EastBanc Technologies, discussed how one organization leveraged IoT, cloud technology and data analysis to improve customer experiences and effici...
Dec. 9, 2016 06:45 PM EST Reads: 5,135
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, discussed why and how ReadyTalk diverted from healthy revenue and mor...
Dec. 9, 2016 06:15 PM EST Reads: 1,760
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Dec. 9, 2016 05:30 PM EST Reads: 2,364
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lead...
Dec. 9, 2016 05:30 PM EST Reads: 467
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
Dec. 9, 2016 05:15 PM EST Reads: 1,884
The Internet of Things (IoT) promises to simplify and streamline our lives by automating routine tasks that distract us from our goals. This promise is based on the ubiquitous deployment of smart, connected devices that link everything from industrial control systems to automobiles to refrigerators. Unfortunately, comparatively few of the devices currently deployed have been developed with an eye toward security, and as the DDoS attacks of late October 2016 have demonstrated, this oversight can ...
Dec. 9, 2016 05:15 PM EST Reads: 1,460
"MathFreeOn.com is a line coding platform for engineers and scientists. When they want to solve an engineering problem and they have to use software - they have to pay a lot of money for licenses - but with MathFreeOn you don't have to pay a lot of money. Just go to our site and write the code and you can check the result right away," explained Simon Lee, CMO of MathFreeOn, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Cla...
Dec. 9, 2016 05:15 PM EST Reads: 397
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, contrasted how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He showed how the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He also demoed building immutable pipelines in the cloud ...
Dec. 9, 2016 05:00 PM EST Reads: 2,066
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
Dec. 9, 2016 04:45 PM EST Reads: 1,863
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
Dec. 9, 2016 04:45 PM EST Reads: 1,298
In his session at Cloud Expo, Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, provideed economic scenarios that describe how the rapid adoption of software-defined everything including cloud services, SDDC and open networking will change GDP, industry growth, productivity and jobs. This session also included a drill down for several industries such as finance, social media, cloud service providers and pharmaceuticals.
Dec. 9, 2016 03:45 PM EST Reads: 597
"Dice has been around for the last 20 years. We have been helping tech professionals find new jobs and career opportunities," explained Manish Dixit, VP of Product and Engineering at Dice, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 9, 2016 03:30 PM EST Reads: 1,238
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 9, 2016 03:15 PM EST Reads: 871